Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U01 Clinical Trial Not Allowed) | RFA DA 25 037

Frequently Asked Questions (FAQs)

What is the TranSINDA funding opportunity (RFA-DA-25-037)?

Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA), RFA-DA-25-037, is a National Institutes of Health (NIH) funding announcement supporting team-based research on how early-life social environments shape brain and behavioral development in ways that increase or decrease later risk for substance use disorders (SUD) and related comorbidities.

What is the main scientific goal of TranSINDA?

The main goal is to move beyond broad correlations and identify the biological and neurocognitive mechanisms that translate early social experiences into lasting changes in neurobehavioral trajectories, especially as individuals transition into adolescence and adulthood when vulnerability to substance use and addiction often increases.

What types of research designs does this NOFO emphasize?

This opportunity specifically emphasizes longitudinal research designs in animal models. That means following development over time (rather than relying on a single timepoint) and using experimental approaches that help clarify cause-and-effect pathways linking early social environments to later outcomes relevant to addiction risk.

Are studies required to use animal models?

Yes. The NOFO emphasizes longitudinal research designs in animal models and describes the scientific scope and expectations in that context.

Is the research expected to be mechanistic (cause-and-effect) rather than descriptive?

Yes. The NOFO highlights the need to pinpoint mechanisms that translate early-life social experiences into measurable, lasting changes in neurocognitive development and behavior relevant to addiction risk, using approaches suited to establishing causal pathways.

What early-life social environmental factors are within scope?

The scientific scope highlights early-life social environmental factors such as aspects of caregiving, social enrichment or deprivation, stress exposures, and related social-context variables, as long as the project connects these exposures to measurable neurocognitive and behavioral outcomes relevant to addiction vulnerability.

What kinds of outcomes or systems should projects connect to addiction risk?

The NOFO indicates interest in brain and behavioral systems involved in learning, reward, stress responsivity, executive function, and other neurocognitive processes tied to substance use vulnerability, with measurable changes tracked over development.

How does the NOFO define the translational expectation?

Although the studies are in animal models, projects are intended to be informed by substance use disorder research in humans as well as animals. Applicants are expected to align animal measures and conceptual models with what is known from human developmental and addiction science so findings can more realistically inform prevention and intervention strategies.

What disciplines, theories, or frameworks does TranSINDA encourage?

The NOFO encourages theories and methods drawn from cognitive development, developmental psychobiology, and developmental neuroscience, reflecting an interest in integrative projects that connect developmental behavioral measurement with advanced neuroscience and analytic approaches.

What kinds of methods are encouraged?

The opportunity calls for advanced neuroscience methods and theoretically grounded frameworks, and notes that projects may integrate neural circuit, molecular, computational, or other sophisticated analytic tools to explain how early social experiences influence neurodevelopmental pathways relevant to addiction risk.

What is the funding mechanism for this opportunity?

The funding mechanism is a U01 cooperative agreement, which generally indicates an active partnership between NIH program staff and the research team compared with a standard investigator-initiated grant.

Are clinical trials allowed under this NOFO?

No. The notice states "Clinical Trial Not Allowed," so applicants should not propose clinical trials under this announcement.

What is the CFDA number associated with this program?

The CFDA number associated with the program is 93.279, which corresponds to NIH substance use and addiction-related funding streams.

Who is eligible to apply?

Eligibility is broad and includes multiple categories across government, academia, nonprofit, and industry. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations (other than small businesses); and small businesses.

Are organizations serving underrepresented populations explicitly included as eligible applicants?

Yes. The NOFO explicitly highlights additional eligible applicant categories including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, historically Black colleges and universities (HBCUs), and tribally controlled colleges and universities (TCCUs).

Can faith-based or community-based organizations apply?

Yes. Faith-based or community-based organizations are explicitly listed among eligible applicant categories.

Can federal agencies apply?

Yes. Eligible federal agencies are listed among the additional eligible applicant categories.

Can non-U.S. (foreign) organizations apply?

Yes. Non-U.S. entities (foreign organizations) are explicitly included as eligible applicants.

Are U.S. territories or possessions eligible to apply?

Yes. U.S. territories or possessions are listed among eligible applicant categories.

What is the application deadline?

The information provided lists an original closing date of November 7, 2024.

When was this opportunity created?

The creation date provided is July 18, 2024.

How many awards will be made, and what is the maximum award amount?

The award ceiling and expected number of awards are not specified in the provided source data. Applicants are expected to consult the full NOFO text for budget guidance, project period expectations, and any programmatic caps or limits.

What should applicants do if they need budget caps, project period limits, or other administrative constraints?

Because the provided summary does not include an award ceiling, expected number of awards, or detailed budget and project period guidance, applicants should consult the full NOFO for those requirements and limits.

What kind of research team structure does TranSINDA support?

The opportunity supports team-based research and uses a U01 cooperative agreement mechanism, signaling a collaborative approach and an active partnership with NIH program staff compared with typical investigator-initiated grants.

What is the overall focus of TranSINDA in one sentence?

TranSINDA supports rigorous, longitudinal animal research that explains how early social environments shape neurocognitive development and neurobehavioral trajectories in ways that influence later addiction risk, with findings framed to connect to human SUD evidence and prevention/intervention relevance.